“The Appetite Switch”
The most well-established GLP-1 agonist, with the longest real-world track record of the metabolic peptides on this list.
Semaglutide activates the GLP-1 receptor, which slows digestion, reduces appetite signals in the brain, and improves insulin response. It's structurally modified to resist rapid breakdown, allowing once-weekly dosing.
Yes, under the brand names Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management).
It's the most established GLP-1 drug on the market, with the longest real-world usage history and the largest published trial dataset of any peptide in this library.
Mostly gastrointestinal: nausea and digestive discomfort are the most frequently reported, particularly during dose increases.
Semaglutide has the deepest evidence base of anything in this library: multiple large randomized trials, years of post-market surveillance, and ongoing research into new applications.
The numbers are only half of it. The Blueprint covers exact dosing per peptide, proven stacks, and step-by-step injection instructions.
The complete peptide reference. 20+ compounds broken down, step-by-step instructions, stack breakdowns, troubleshooting, and a 30% sourcing discount code.
Learn More · $40